INDIANAPOLIS, Nov. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today patients with active psoriatic arthritis (PsA) treated with Taltz ® (ixekizumab), who were previously ...
Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment of ...
New York, USA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight TALTZ ...
Eli Lilly reported that Taltz (ixekizumab) achieved primary and secondary endpoints in SPIRIT-P2, a Phase 3 clinical trial evaluating the treatment in psoriatic arthritis (PsA). These results were ...
Results from first network meta-analysis based on area under the curve of 52-week clinical trial data. Taltz also helped patients stay on treatment longer and have more days without additional therapy ...
Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out on ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Taltz was effective treatment for ...
INDIANAPOLIS, March 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application ...
Eli Lilly now has approval for its new psoriasis treatment Taltz on both sides of the Atlantic after the European Commission granted marketing authorisation for the drug. The interleukin-17 (IL-17) ...
Eli Lilly and Co. has won federal approval to market its hot-selling anti-inflammatory drug Taltz for another use: treatment of a type of arthritis that does not show any structural body damage on ...
TALTZ The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback